GlassScriptPhysician profile
Courtney Travis
NPI 1376910166
$2,269.83
in general payments reported to CMS, 2019-2025
25 companies · $634 in 2025
The $634 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $219 · 2023: $492 · 2024: $314 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $487.58 | 2021-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $406.90 | 2021-2025 | Ztlido |
| Curonix LLC | $204.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.47 | 2024-2025 | Relistor, Trulance |
| Biodelivery Sciences International, INC. | $175.31 | 2021 | |
| Boston Scientific Corporation | $89.04 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Redhill Biopharma INC. | $78.20 | 2021 | |
| Medtronic, INC. | $66.96 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $56.90 | 2021 | |
| Amneal Pharmaceuticals LLC | $52.53 | 2023 | Lyvispah |
| Genzyme Corporation | $52.11 | 2025 | |
| Azurity Pharmaceuticals, INC. | $49.10 | 2023-2024 | Horizant, Horizant |
| Fidia Pharma USA INC. | $46.87 | 2021-2025 | Hymovis, Triluron |
| Arbor Pharmaceuticals, INC. | $42.78 | 2022 | |
| Vertos Medical, INC. | $39.01 | 2023-2024 | Mild Device Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $30.64 | 2025 | Evoke |
| Averitas Pharma INC. | $30.12 | 2023 | Qutenza |
| Tonix Medicines, INC. | $28.93 | 2025 | Tonmya |
| Daiichi Sankyo INC. | $28.12 | 2024 | Enhertu |
| Vertex Pharmaceuticals Incorporated | $20.76 | 2025 | |
| Stimwave Technologies Incorporated | $18.91 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.53 | 2021 | |
| Grt US Holding, INC. | $15.26 | 2021 | |
| Almatica Pharma LLC | $14.48 | 2023 | Gralise |
| Pfizer INC. | $14.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.